| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
As a protected dipeptide intermediate, benzyl (tert-butoxycarbonyl)-L-leucyl-L-phenylalaninate does not possess direct biological targets. Its role is upstream of pharmacology, serving as a building block for peptide drugs. For example, Carfilzomib, a proteasome inhibitor used in multiple myeloma, contains this dipeptide motif in its synthetic route. Thus, its downstream target is the 20S proteasome, but the intermediate itself has no inherent bioactivity. It is classified as an Amino Acid Derivative with a target pathway in the "Others" category.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
This compound is not a pharmacologically active agent and therefore has no direct in vitro biological activity data. No studies report cytotoxicity, enzyme inhibition, or receptor modulation for this intermediate. Any in vitro activity would be attributed to the final synthesized peptide or drug (e.g., Carfilzomib), not the protected dipeptide precursor itself. In the context of chemical synthesis, it serves as a substrate for peptide coupling reactions. |
| ln Vivo |
No in vivo biological activity data are available for this compound because it is exclusively a synthetic intermediate. It has not been evaluated in animal models for efficacy against any disease condition, as it requires deprotection (removal of Boc and benzyl groups) to generate the active peptide. Carfilzomib, derived from such intermediates, is administered intravenously in animal models of multiple myeloma.
|
| Enzyme Assay |
The compound is not used in enzyme or receptor binding assays. Instead, standard peptide chemistry protocols describe its use as a protected dipeptide. A typical chemical synthesis protocol: In solution-phase peptide synthesis, 1.0 eq of Boc-Leu-OH is activated with HOBt and DCC at 0degC in DMF or DCM. Separately, H-Phe-OBzl (the benzyl ester) is neutralized with N-methylmorpholine. The activated Boc-Leu-OH is added, and the reaction is stirred at room temperature for 12-24 hours. The product is extracted with ethyl acetate, washed, dried, and purified by column chromatography. Alternatively, this compound can be prepared via SPPS using standard Fmoc/Boc strategies on a solid support.
|
| Cell Assay |
No cell-based protocols are established for this synthetic intermediate, as it is not bioactive. In general handling, the compound is dissolved in DMSO (stock solution: 100 mM) or DMF for peptide coupling reactions, but it is not added to cell culture. For evaluating peptides synthesized from this intermediate, a typical protocol involves seeding cancer cells (e.g., RPMI-8226 multiple myeloma cells) in 96-well plates (10,000 cells/well), treating with the deprotected peptide for 48 hours, and measuring viability by MTT or CellTiter-Glo.
|
| Animal Protocol |
No in vivo animal experiments have been conducted with this protected dipeptide directly. However, for Carfilzomib or similar drugs synthesized from this intermediate, a typical study: Female CB-17 SCID mice are injected intravenously with 5×10⁶ RPMI-8226 or MM.1S multiple myeloma cells. When tumors reach 150 mm3, mice receive intravenous Carfilzomib at 2-5 mg/kg twice weekly for 2-4 weeks. Tumor volume is measured by calipers, and survival is monitored. The intermediate itself is not administered.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data are available for benzyl (tert-butoxycarbonyl)-L-leucyl-L-phenylalaninate. It is not a drug candidate, and ADME properties have not been studied. As a dipeptide with protecting groups, it would be rapidly hydrolyzed and metabolized if administered. In contrast, Carfilzomib (the final drug) has a half-life of 30-60 minutes, low oral bioavailability, and is administered intravenously. The intermediate is stored as a powder at -20degC, stable for 3 years.
|
| Toxicity/Toxicokinetics |
According to safety data sheets, this compound may cause skin and eye irritation. It is harmful if swallowed (oral LD50 >2000 mg/kg predicted). Inhalation of dust may cause respiratory irritation. Not classified as carcinogen or mutagen. Standard laboratory precautions: gloves, safety goggles, lab coat, fume hood. In case of contact, flush with water. The compound is stable under recommended storage conditions.
|
| References | |
| Additional Infomation |
Slight variations exist: This compound is Carfilzomib Impurity 66. It may also be referred to as Carfilzomib intermediate. Carfilzomib (Kyprolis) is an FDA-approved drug for relapsed/refractory multiple myeloma. This intermediate highlights the significance of protected dipeptides in pharmaceutical synthesis. Unlike active drugs, this intermediate is exclusively a research chemical for peptide synthesis. No clinical trials involve this intermediate. It is supplied by chemical vendors for research only.
|
| Molecular Formula |
C27H36N2O5
|
|---|---|
| Molecular Weight |
468.59
|
| Exact Mass |
468.262
|
| CAS # |
70637-26-2
|
| PubChem CID |
15138263
|
| Appearance |
White to light yellow solid powder
|
| LogP |
5.178
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
34
|
| Complexity |
646
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(C[C@H](NC(OC(C)(C)C)=O)C(N[C@H](C(OCC1=CC=CC=C1)=O)CC2=CC=CC=C2)=O)C
|
| InChi Key |
IKZFNIAMQFYRSM-GOTSBHOMSA-N
|
| InChi Code |
InChI=1S/C27H36N2O5/c1-19(2)16-22(29-26(32)34-27(3,4)5)24(30)28-23(17-20-12-8-6-9-13-20)25(31)33-18-21-14-10-7-11-15-21/h6-15,19,22-23H,16-18H2,1-5H3,(H,28,30)(H,29,32)/t22-,23-/m0/s1
|
| Chemical Name |
benzyl (2S)-2-[[(2S)-4-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoyl]amino]-3-phenylpropanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (213.41 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.34 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1341 mL | 10.6703 mL | 21.3406 mL | |
| 5 mM | 0.4268 mL | 2.1341 mL | 4.2681 mL | |
| 10 mM | 0.2134 mL | 1.0670 mL | 2.1341 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
